Hyd-based Zenara Pharma launches Paxzen to treat mild to moderate Covid-19

Hyderabad: Hyderabad-based Zenara Pharma, a fully owned subsidiary of Biophore India Pharmaceuticals, has launched Nirmatrelvir and Ritonavir tablets in a combi pack as a treatment option for patients with mild to moderate symptoms of Covid-19.

Zenara Pharma received approval from the Central Drugs Standard Control Organization (CDSCO) to manufacture and market this product. The tablet, which will be sold under the brand name 'Paxzen', is being manufactured at Zenara's US FDA and EU-approved state-of-the-art facility in Hyderabad.

The product will be sold at a maximum retail price of Rs. 5,200 per box, equivalent to one full course of treatment per patient, and contains 20 tablets of Nirmatrelvir (150ml) and 10 tablets of Ritonavir (100mg).

Dr. Jagadeesh Babu Rangisetty, the co-founder and managing director at Zenara Pharma, said they launched the product in India to make available to patients the best treatment options against Covid-19. "Our product, Paxzen, has been proven equivalent to Paxlovid through a bioequivalence study, based on which we have received the approval from the regulatory authorities," he said.

This product's breakthrough approval in the US was given by the US FDA in December 2021 and is indicated for the treatment of mild-to-moderate Covid-19 in adults. It was the first oral pill approved by US FDA and with a better safety profile than subsequently approved oral therapies.

Dr. Rangisetty added, "We have ensured that the product will be available to all patients by placing the product with our distribution partners spread across India and their details can be accessed through our dedicated helpline number 72079 28889 and also through our website. Patients or hospitals may call or Whatsapp this number for availability and we will ensure that they can access Paxzen at the earliest."